Has Isida Byku, MD received payments from drug or device companies?

Yes. Drug and device makers reported $77,699 in general payments to Isida Byku, MD across 125 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Isida Byku, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Isida Byku, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Isida Byku, MD

Cardiovascular Disease · Atlanta, GANPI 1457650871

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $62,588 of the $77,699 with a category attached, or 80.6%. Edwards Lifesciences accounts for 90.1% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $66,875, more than ten times the $2,138 reported in 2019. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$77,699in general payments, 2019–2025

Across 125 payments — averaging $621.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Edwards Lifesciences$70K
Medtronic$2K
Shockwave Medical, Inc$2K
Abbott$1K
Boston Scientific$950
Angiodynamics, Inc.$735
plus $268 from 4 others

$86,918in research payments, 2019–2025

Across 15 payments — averaging $5794.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$87K

What the payments were for

Consulting fees$62,58881%
Travel & lodging$9,08112%
Food & beverage$6,0308%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Edwards Lifesciences	68	$70,005
Medtronic(2 entities)	18	$2,360
Shockwave Medical, Inc	5	$2,156
Abbott	10	$1,224
Boston Scientific	13	$950
Angiodynamics, Inc.	6	$735
W. L. Gore & Associates, Inc.	2	$88
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$82
Abiomed	1	$51
Amgen	1	$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Edwards SAPIEN 3 Transcatheter Heart Valve$65,599
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,964
CoreValve Evolut$1,517
EVOQUE$1,043
AlphaVac$598
Vascular Lithotripsy$162
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$161
GENERAL - THERAPIES$159
COREVALVE EVOLUT R$154
Mitra Clip system$147
OPTICROSS$128
SAPIEN 3 Ultra RESILIA$118
COMET$108
Resolute$106
AVVIGO Guidance System$105

How this compares

$77,699 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia →

Medicare billing

Part B allowed, 2024

$184,242

Medicare patients

239

Services billed

686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	97	$81,862
EntrestoSacubitril/Valsartan	23	$20,071
FarxigaDapagliflozin Propanediol	13	$9,568
Metoprolol Succinate	121	$1,410
Potassium Chloride	12	$1,246
Rosuvastatin Calcium	104	$1,246
Atorvastatin Calcium	98	$952
ClopidogrelClopidogrel Bisulfate	71	$650
Carvedilol	73	$562
Ranolazine ErRanolazine	14	$489
Ezetimibe	27	$448
Amlodipine Besylate	75	$342
Torsemide	30	$329
Valsartan	18	$325
Verapamil SrVerapamil Hcl	14	$308

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Atlanta

Joseph MillerAtlanta$573K
Utpal PandyaAtlanta$221K
Randolph MartinAtlanta$177K
Mani VannanAtlanta$157K
Victor CorriganAtlanta$114K
Elizabeth OfiliAtlanta$107K
Cindy GrinesAtlanta$75K
Anekwe OnwuanyiAtlanta$56K
Melvin EcholsAtlanta$51K
Venkateshwar PolsaniAtlanta$49K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →